NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

The World Mosquito Program (WMP) of Monash University and Debug by Alphabet announced today that they are teaming up to explore a collaboration to deploy automated releases of Wolbachia Aedes aegypti ...

The following is a summary of “Transcriptomic insights into early mechanisms underlying post-chikungunya chronic inflammatory ...

Five people have been hospitalized with cardiac and neurological symptoms after getting the chikungunya vaccine.

The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine ...

Bavarian Nordic, a Danish biotechnology company specializing in vaccine development, was on 28 February 2025 granted ...

Mosquito resistance in Costa Rica is rising, threatening dengue control in 2025. Discover why and how to fight back with ...

If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and ...

The US Centers for Disease Control and Prevention is currently investigating five hospitalizations that occurred in people ...

The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the competition with Valneva by countering with a label that covers a broader population.

The FDA has approved Bavarian Nordic’s Vimkunya, the first virus-like particle (VLP) chikungunya vaccine for patients over 12 years of age. According to the company, approval was based on strong ...

The Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™ (chikungunya vaccine, recombinant) for the prevention of disease caused by chikungunya virus (CHIKV ...